Abstract
The current literature review covers the role of sympathetic nervous system activation (SNS) and the significance of a new biomarker catestatin (CST), which is a chromogranin A-derived peptide, for assessing prognosis of patients with heart failure (HF). This review details the works devoted to CST metabolism and its role in clinical conditions with excessive catecholamine production, including the ability to counterbalance the adverse effects of SNS on cardiovascular system. The paper also presents the central results of studies on HF patients and shows the correlation of the CST level with HF functional class and stage. In addition, particular attention is paid on the possibilities and potential benefits of assessing the CST in addition to conventional management of patients hospitalized due to acute decompensated heart failure.
Highlights
Данная обзорная статья посвящена роли активации симпатической нервной системы (СНС) и значению определения концентрации нового биомаркера-производного хромогранина А катестатина (CST) для оценки прогноза больных с сердечной недостаточностью
The current literature review covers the role of sympathetic nervous system activation (SNS) and the significance of a new biomarker catestatin (CST), which is a chromogranin A-derived peptide, for assessing prognosis of patients with heart failure (HF)
This review details the works devoted to CST metabolism and its role in clinical conditions with excessive catecholamine production, including the ability to counterbalance the adverse effects of SNS on cardiovascular system
Summary
Данная обзорная статья посвящена роли активации симпатической нервной системы (СНС) и значению определения концентрации нового биомаркера-производного хромогранина А катестатина (CST) для оценки прогноза больных с сердечной недостаточностью. В настоящее время одним из наиболее перспективных маркеров является катестатин (CST) — супрессор и ингибитор высвобождения катехоламинов, отражающий повышенную активность СНС при СН, и действующий как компенсаторный негативный регулятор метаболизма катехоламинов, в то время как более высокие уровни CST являются независимым предиктором общей и сердечно-сосудистой смертности у пациентов с ХСН [17].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
